Pharma channel feed

J&J ac­cused of de­fraud­ing US Patent Of­fice in an­ti-com­pe­ti­tion law­suit

Last year
Law

ICER un­veils lat­est re­port on 'un­sup­port­ed' drug price in­creas­es

Last year
FDA+

Cor­rect­ed: BeiGene builds out long-term case for Brukin­sa in CLL with three-year fol­low-up da­ta

Last year
R&D

As cash runs tight, blue­bird plunges af­ter pric­ing sick­le cell gene ther­a­py well above com­peti­tor and fail­ing to win re­view vouch­er

Last year
Cell/Gene Tx

Ab­b­Vie teams with Parkin­son’s dis­ease foun­da­tion for 'Flip­ping the Switch' ef­fort

Last year
Marketing

New re­search points to po­ten­tial link be­tween GLP-1s and low­ered risk of col­orec­tal can­cer

Last year

Think phar­ma ads have too many celebri­ties and jin­gles? Not many ac­tu­al­ly use them, study finds

Last year
Marketing

Gavi an­nounces $1.8B for vac­cine ac­cess, pan­dem­ic pre­pared­ness ef­forts in Africa

Last year
R&D
Manufacturing

FDA ap­proves two gene ther­a­pies for sick­le cell dis­ease, in­clud­ing first that us­es CRISPR

Last year
FDA+

Bris­tol My­ers’ lead deal ne­go­tia­tor to de­part af­ter ink­ing se­ries of multi­bil­lion-dol­lar ac­qui­si­tions

Last year
People

Biden pro­pos­al on 'march-in' rights would have lim­it­ed ef­fect on cur­rent drug costs, crit­ics say

Last year
FDA+

Sen. Klobuchar calls out Ris­ing Phar­ma for price-goug­ing an old gener­ic drug in short­age

Last year

Physi­cians are start­ing to shift phar­ma sales rep mod­els from push to pull, study finds

Last year
Marketing

Mer­ck halts tri­al af­ter Keytru­da-Lyn­parza com­bo flunks PhI­II study in lung can­cer

Last year

House com­mit­tee ad­vances key PBM bills in step with Sen­ate coun­ter­parts

Last year
FDA+

Van­da buys J&J's mul­ti­ple scle­ro­sis drug Pon­vory for $100M

Last year
Deals

Three big win­ners from Ab­b­Vie's $8.7B Cerev­el deal: A drug­mak­er, a CEO and a SPAC

Last year
People
Deals

Biden ad­min­is­tra­tion lays foun­da­tion for use of march-in rights as it talks up drug price goals

Last year
FDA+

Sanofi CEO Paul Hud­son pitch­es 12 block­busters in a bid to con­vince in­vestors on boost­ing R&D spend

Last year
R&D

Ab­b­Vie bets that near­ly $20B in deals can bring it in­to the post-Hu­mi­ra fu­ture

Last year
Deals

NASH drug­mak­er He­p­i­on to seek strate­gic al­ter­na­tives

Last year
People

Ab­b­Vie makes sec­ond deal in a week, bet­ting $8.7B in cash on CNS biotech Cerev­el 

Last year
Deals

US Patent Tri­al and Ap­peal Board to re­con­sid­er Spruce patents around treat­ment for adren­al dis­or­der

Last year
Law

Klick Health's an­nu­al hol­i­day greet­ing plays Se­cret San­ta for its own em­ploy­ees

Last year
Marketing
First page Previous page 85868788899091 Next page Last page
A service from the Financial Times